Biotech's Patent Suite Catches Sparks From Federal Circuit's Prometheus Decision

Pharmaceutical and biotech firms will have broader patent protection after an appeals court drew a narrow definition of what constitutes a natural phenomenon in the biotech arena. Specifically, the court ruled that a test to measure a drug's metabolites in order to determine the proper drug dosage is patentable subject matter

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet